{
    "nct_id": "NCT06586671",
    "official_title": "An Open-Label, Two-Part, Two-Period Crossover Study to Determine Bioequivalence Between Nemtabrutinib FFP and FMF2 Formulations & FMF1 and FMF2 Formulations at 65 mg Single Dose in Healthy Male Participants",
    "inclusion_criteria": "The key inclusion criteria include but are not limited to the following:\n\n* Is in good health before randomization\n* Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 45 Years",
    "exclusion_criteria": "The key exclusion criteria include but are not limited to the following:\n\n* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases\n* Has a history of cancer with pre-specified exceptions (adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study, per protocol guidelines)",
    "miscellaneous_criteria": ""
}